GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Idorsia Ltd (CHIX:IDIAz) » Definitions » Loans Receivable

Idorsia (CHIX:IDIAZ) Loans Receivable : CHF0.0 Mil (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Idorsia Loans Receivable?

Idorsia's Loans Receivable for the quarter that ended in Dec. 2024 was CHF0.0 Mil.


Idorsia Loans Receivable Historical Data

The historical data trend for Idorsia's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Idorsia Loans Receivable Chart

Idorsia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Loans Receivable
Get a 7-Day Free Trial Premium Member Only - - - - -

Idorsia Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Idorsia Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Idorsia Loans Receivable Related Terms

Thank you for viewing the detailed overview of Idorsia's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Idorsia Business Description

Traded in Other Exchanges
Address
Hegenheimermattweg 91, Allschwil, CHE, 4123
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide innovative therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.

Idorsia Headlines

No Headlines